

# Carle F Paul

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7259952/publications.pdf>

Version: 2024-02-01

359  
papers

20,177  
citations

8181

76  
h-index

14759

127  
g-index

396  
all docs

396  
docs citations

396  
times ranked

12922  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and 3): a randomised, double-blind, placebo-controlled, phase 3b study. <i>Lancet</i> , 2017, 389, 2040-2050.	13.7	7195
2	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , 2015, 373, 1318-1328.	27.0	656
3	First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. <i>Lancet</i> , 2017, 389, 2031-2040.	13.7	438
4	Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 871-881.e30.	1.2	423
5	Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). <i>British Journal of Dermatology</i> , 2015, 173, 1387-1399.	1.5	384
6	A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2016, 175, 273-286.	1.5	378
7	European S3 Guidelines on the systemic treatment of psoriasis vulgaris â€“ Update 2015 â€“ Short version â€“ <sc>EDF</sc> in cooperation with <sc>EADV</sc> and <sc>IPC</sc>. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2277-2294.	2.4	353
8	Risk of Malignancies in Psoriasis Patients Treated with Cyclosporine: a 5 y Cohort Study. <i>Journal of Investigative Dermatology</i> , 2003, 120, 211-216.	0.7	328
9	Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children. <i>Pediatrics</i> , 2002, 110, e2-e2.	2.1	315
10	Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (<sc>JUNCTURE</sc>). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1082-1090.	2.4	254
11	Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 110, 277-284.	2.9	250
12	Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. <i>British Journal of Dermatology</i> , 1996, 134, 710-714.	1.5	248
13	Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 12-29.	2.4	248
14	Carcinogenic risks of Psoralen UVâ€A therapy and Narrowband UVâ€B therapy in chronic plaque psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 22-31.	2.4	246
15	Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2021, 384, 1101-1112.	27.0	239
16	Risk of Lymphoma Following Exposure to Calcineurin Inhibitors and Topical Steroids in Patients with Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2007, 127, 808-816.	0.7	233
17	The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. <i>British Journal of Dermatology</i> , 2001, 144, 507-513.	1.5	232
18	What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 10-16.	2.4	229

#	ARTICLE	IF	CITATIONS
19	Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 242-248.	1.2	222
20	ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2717-2744.	2.4	220
21	Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1094-1102.	2.9	212
22	Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK Signaling. <i>Circulation</i> , 2017, 136, 1037-1048.	1.6	204
23	Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study. <i>British Journal of Dermatology</i> , 2012, 168, no-no.	1.5	199
24	Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 576-586.	13.7	198
25	Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 36-46.	2.4	194
26	Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. <i>New England Journal of Medicine</i> , 2020, 382, 706-716.	27.0	189
27	Long-term Effectiveness of Treatment With Terbinafine vs Itraconazole in Onychomycosis. <i>Archives of Dermatology</i> , 2002, 138, 353-7.	1.4	181
28	Bimekizumab versus Secukinumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021, 385, 142-152.	27.0	173
29	Quantification of <i>Demodex folliculorum</i> by PCR in rosacea and its relationship to skin innate immune activation. <i>Experimental Dermatology</i> , 2012, 21, 906-910.	2.9	171
30	Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 1111-1117.	5.7	169
31	Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 992-1002.	1.2	162
32	Chronic Dermatofungal Infections of the Foot as Risk Factors for Acute Bacterial Cellulitis of the Leg: A Case-Control Study. <i>Dermatology</i> , 2004, 209, 301-307.	2.1	161
33	Adherence to topical treatment in psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 61-67.	2.4	161
34	Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. <i>British Journal of Dermatology</i> , 2017, 177, 1014-1023.	1.5	155
35	Staphylococcus aureus density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1272-1274.e3.	2.9	146
36	Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: A 2-year cohort study. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 643-651.	1.2	142

#	ARTICLE	IF	CITATIONS
37	Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2002-2010.	2.4	139
38	Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. <i>British Journal of Dermatology</i> , 2004, 150, 96-102.	1.5	136
39	Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 12-18.	2.4	135
40	Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 801-806.	5.7	134
41	Cyclosporin in psoriasis clinical practice: an international consensus statement. <i>British Journal of Dermatology</i> , 2004, 150, 11-23.	1.5	132
42	Prognostic Factors of Paraneoplastic Pemphigus. <i>Archives of Dermatology</i> , 2012, 148, 1165.	1.4	125
43	Update on the epidermal differentiation complex. <i>Frontiers in Bioscience - Landmark</i> , 2012, 17, 1517.	3.0	125
44	Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. <i>British Journal of Dermatology</i> , 1999, 141, 283-291.	1.5	124
45	Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 31-35.	2.4	124
46	Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. <i>British Journal of Dermatology</i> , 2001, 144, 967-972.	1.5	123
47	Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. <i>British Journal of Dermatology</i> , 2009, 160, 622-628.	1.5	121
48	Alcohol consumption and psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 30-35.	2.4	121
49	Psoriasis: rationale for targeting interleukin-17. <i>British Journal of Dermatology</i> , 2012, 167, 717-724.	1.5	120
50	Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 23-30.	2.4	119
51	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 291-304.	3.4	119
52	Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial*. <i>British Journal of Dermatology</i> , 2021, 184, 50-59.	1.5	119
53	Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. <i>British Journal of Dermatology</i> , 2013, 168, 402-411.	1.5	118
54	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 266-276.e5.	1.2	117

#	ARTICLE	IF	CITATIONS
55	European S3â€œGuideline on the systemic treatment of psoriasis vulgaris â€œ Update Apremilast and Secukinumab â€œ <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1951-1963.	2.4	116
56	What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 17-22.	2.4	114
57	A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. British Journal of Dermatology, 2002, 147, 518-522.	1.5	111
58	Knockdown of Filaggrin in a Three-Dimensional Reconstructed Human Epidermis Impairs Keratinocyte Differentiation. Journal of Investigative Dermatology, 2014, 134, 2938-2946.	0.7	111
59	Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. Journal of the American Academy of Dermatology, 2017, 76, 432-440.e17.	1.2	111
60	Safety and Tolerability of 1% Pimecrolimus Cream Among Infants: Experience With 1133 Patients Treated for Up to 2 Years. Pediatrics, 2006, 117, e118-e128.	2.1	109
61	Prevalence and Risk Factors for Xerosis in the Elderly: A Cross-Sectional Epidemiological Study in Primary Care. Dermatology, 2011, 223, 260-265.	2.1	107
62	Longâ€œterm safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. Journal of Dermatological Treatment, 2004, 15, 169-178.	2.2	103
63	Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: A two-year study. Journal of the American Academy of Dermatology, 2005, 52, 240-246.	1.2	101
64	Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in nonâ€œplaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 19-27.	2.4	100
65	European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARSâ€œCovâ€œ2) infection and atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e241-e242.	2.4	99
66	Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study. American Journal of Hematology, 2010, 85, 921-925.	4.1	98
67	Clinical meaningfulness of complete skin clearance in psoriasis. Journal of the American Academy of Dermatology, 2016, 75, 77-82.e7.	1.2	96
68	Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet, The, 2017, 389, 612-620.	13.7	95
69	Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSOâ€œABLE study. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 119-126.	2.4	92
70	Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. British Journal of Dermatology, 2012, 167, 1138-1144.	1.5	91
71	Psoriasis: an epidemiological evaluation of disease burden in 590 patients. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1075-1082.	2.4	87
72	Terbinafine in the Treatment of Trichophyton Tinea Capitis: A Randomized, Double-Blind, Parallel-Group, Duration-Finding Study. Pediatrics, 2002, 109, 602-607.	2.1	85

#	ARTICLE	IF	CITATIONS
73	European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1644-1659.	2.4	85
74	A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to <i>Microsporum</i> species. <i>British Journal of Dermatology</i> , 2002, 146, 816-823.	1.5	80
75	Hornerin is a component of the epidermal cornified cell envelopes. <i>FASEB Journal</i> , 2011, 25, 1567-1576.	0.5	80
76	Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). <i>British Journal of Dermatology</i> , 2018, 178, 674-681.	1.5	80
77	Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 247-253.	1.2	78
78	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 839-846.	1.2	78
79	A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. <i>British Journal of Dermatology</i> , 2013, 168, 1080-1087.	1.5	77
80	Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 70-79.e3.	1.2	77
81	Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1670-1675.	2.4	75
82	Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer.. <i>BMJ: British Medical Journal</i> , 1989, 299, 759-762.	2.3	74
83	A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. <i>British Journal of Dermatology</i> , 2007, 157, 954-959.	1.5	72
84	Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 17-26.	2.4	72
85	Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. <i>Pediatric Allergy and Immunology</i> , 2015, 26, 306-315.	2.6	71
86	Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 2-11.	2.4	70
87	Deimination of Human Filaggrin-2 Promotes Its Proteolysis by Calpain 1. <i>Journal of Biological Chemistry</i> , 2011, 286, 23222-23233.	3.4	70
88	Segmental and nonsegmental childhood vitiligo has distinct clinical characteristics: A prospective observational study. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 945-949.	1.2	69
89	Efficacy and tolerability of methotrexate in severe childhood alopecia areata. <i>British Journal of Dermatology</i> , 2011, 165, 407-410.	1.5	69
90	EMLA cream as a topical anesthetic for the repeated mechanical debridement of venous leg ulcers: A double-blind, placebo-controlled study. <i>Journal of the American Academy of Dermatology</i> , 1999, 40, 208-213.	1.2	68

#	ARTICLE	IF	CITATIONS
91	Potential New Indications of Topical Calcineurin Inhibitors. <i>Dermatology</i> , 2007, 215, 45-54.	2.1	68
92	Calculation of cutoff values based on the Autoimmune Bullous Skin Disorder Intensity Score ( ) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7 for defining moderate, significant and extensive types of pemphigus. <i>British Journal of Dermatology</i> , 2016, 175, 142-149.	1.5	68
93	Epidermodysplasia verruciformis-like eruption complicating human immunodeficiency virus infection. <i>British Journal of Dermatology</i> , 1998, 139, 122-127.	1.5	66
94	Regulation of expression of the ratSOCS-3gene in hepatocytes by growth hormone, interleukin-6 and glucocorticoids. <i>FEBS Journal</i> , 2000, 267, 5849-5857.	0.2	65
95	Ascomycins: promising agents for the treatment of inflammatory skin diseases. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 69-77.	4.1	65
96	Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: A randomized, investigator-blind comparison. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 602-609.	1.2	64
97	CONSORT adoption and quality of reporting of randomized controlled trials: a systematic analysis in two dermatology journals. <i>British Journal of Dermatology</i> , 2009, 161, 1159-1165.	1.5	64
98	Evidenceâ€based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 2-9.	2.4	62
99	Oral contraceptives and risk of breast cancer. <i>International Journal of Cancer</i> , 1990, 46, 366-373.	5.1	61
100	Efficacy of Psoralen UVâ€A therapy vs. Narrowband UVâ€B therapy in chronic plaque psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 11-21.	2.4	60
101	Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1238-1240.	2.4	59
102	Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006, 61, 375-381.	5.7	56
103	Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases. <i>British Journal of Dermatology</i> , 2009, 161, 660-663.	1.5	56
104	Evidenceâ€based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1-10.	2.4	56
105	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. <i>Journal of Investigative Dermatology</i> , 2019, 139, 31-37.	0.7	55
106	Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroidâ€sparing effect. <i>British Journal of Dermatology</i> , 2020, 182, 1111-1119.	1.5	55
107	Effect of Terbinafine on the Pharmacokinetics and Pharmacodynamics of Desipramine in Healthy Volunteers Identified as Cytochrome P450 2D6 (CYP2D6) Extensive Metabolizers. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 1211-1218.	2.0	53
108	Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. <i>British Journal of Dermatology</i> , 2005, 152, 1219-1227.	1.5	53

#	ARTICLE	IF	CITATIONS
109	Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 47-51.	2.4	53
110	Why Statistics Matter: Limited Inter-Rater Agreement Prevents Using the Psoriasis Area and Severity Index as a Unique Determinant of Therapeutic Decision in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2171-2175.	0.7	52
111	Pruritus in Cutaneous T-cell Lymphomas: Frequent, Often Severe and Difficult to Treat. <i>Acta Dermato-Venereologica</i> , 2010, 90, 12-17.	1.3	51
112	Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 28-33.	2.4	51
113	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2020, 10, 133-150.	3.0	51
114	<i>in vivo</i> quantification of epidermis pigmentation and dermis papilla density with reflectance confocal microscopy: variations with age and skin phototype. <i>Experimental Dermatology</i> , 2012, 21, 281-286.	2.9	50
115	Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. <i>Journal of Dermatological Treatment</i> , 2015, 26, 103-112.	2.2	50
116	Omalizumab in the treatment of adult patients with mastocytosis: A systematic review. <i>Clinical and Experimental Allergy</i> , 2020, 50, 654-661.	2.9	50
117	Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. <i>Archives of Dermatology</i> , 1997, 133, 867-871.	1.4	49
118	Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1491-1496.	2.4	47
119	Body-Weight-Independent Dosing of Cyclosporine Micro-Emulsion and Three Times Weekly Maintenance Regimen in Severe Psoriasis. <i>Dermatology</i> , 2002, 205, 383-388.	2.1	46
120	Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 2-11.	2.4	46
121	Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2005, 152, 1296-1303.	1.5	44
122	Photodistribution of Blue-Gray Hyperpigmentation After Amiodarone Treatment. <i>Archives of Dermatology</i> , 2008, 144, 92-6.	1.4	44
123	Consensus recommendations for the treatment of basal cell carcinomas in <i>G</i> orlin syndrome with topical methylaminolaevulinate-photodynamic therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 626-632.	2.4	44
124	Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled <i>JUNCTURE</i> trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 847-856.	2.4	44
125	Drug-induced linear IgA disease: target antigens are heterogeneous. <i>British Journal of Dermatology</i> , 1997, 136, 406-411.	1.5	44
126	Efficacy and Safety of Tumor Necrosis Factor Inhibitors in Acute Generalized Pustular Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 1423.	1.4	42

#	ARTICLE	IF	CITATIONS
127	Topical vitamin D analogues alone or in association with topical steroids for psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 52-60.	2.4	42
128	Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0145076.	2.5	42
129	Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1753-1759.	2.4	42
130	Hyperkeratotic spicules and monoclonal gammopathy. <i>Journal of the American Academy of Dermatology</i> , 1995, 33, 346-351.	1.2	41
131	Interferon Alpha and Pamidronate in Osteoporosis with Fracture Secondary to Mastocytosis. <i>American Journal of Medicine</i> , 2011, 124, 776-778.	1.5	41
132	Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate to severe atopic dermatitis from the BREEZE AD7 Phase 3 randomized trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1543-1552.	2.4	41
133	An Update on the Safety and Tolerability of Pimecrolimus Cream 1%: Evidence from Clinical Trials and Post-Marketing Surveillance. <i>Dermatology</i> , 2007, 215, 27-44.	2.1	40
134	Long-term efficacy of antifungals in toenail onychomycosis: a critical review. <i>British Journal of Dermatology</i> , 2001, 145, 446-452.	1.5	39
135	High-frequency ultrasonography but not 930nm optical coherence tomography reliably evaluates melanoma thickness <i>in vivo</i> : a prospective validation study. <i>British Journal of Dermatology</i> , 2014, 171, 799-805.	1.5	39
136	One week terbinafine 1% cream (Lamisil®) once daily is effective in the treatment of interdigital tinea pedis: a vehicle controlled study. <i>Medical Mycology</i> , 2001, 39, 335-340.	0.7	38
137	Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients. <i>British Journal of Dermatology</i> , 2010, 162, 830-834.	1.5	37
138	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate to severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 435-444.	1.5	37
139	Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study. <i>British Journal of Dermatology</i> , 2017, 176, 1195-1203.	1.5	37
140	Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 360-368.	1.2	37
141	Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 293-300.	2.4	36
142	Terbinafine (LamisilR) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial. <i>British Journal of Dermatology</i> , 2002, 146, 254-260.	1.5	35
143	Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1038-1044.	1.2	35
144	Cellular phone addiction and allergic contact dermatitis to nickel. <i>Contact Dermatitis</i> , 2007, 57, 130-131.	1.4	34

#	ARTICLE	IF	CITATIONS
145	Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 36-46.	2.4	34
146	Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. <i>International Journal of Dermatology</i> , 2004, 43, 978-983.	1.0	33
147	Prevalence and prognostic value of cutaneous manifestations in patients with myelodysplastic syndrome. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1171-1175.	2.4	33
148	Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. <i>British Journal of Dermatology</i> , 2020, 182, 304-315.	1.5	33
149	The biological basis of disease recurrence in psoriasis: a historical perspective and current models. <i>British Journal of Dermatology</i> , 2022, 186, 773-781.	1.5	32
150	Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). <i>British Journal of Dermatology</i> , 2022, 187, 338-352.	1.5	32
151	Prognostic factors of mycological cure following treatment of onychomycosis with oral antifungal agents. <i>British Journal of Dermatology</i> , 2002, 147, 1241-1243.	1.5	31
152	Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. <i>British Journal of Dermatology</i> , 2012, 167, 643-648.	1.5	31
153	Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 224-231.	2.4	31
154	Dermatology today and tomorrow: from symptom control to targeted therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 3-36.	2.4	31
155	Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel®; SDZ ASM 981): impact on quality of life and health-related quality of life. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 248-254.	2.4	30
156	Clinical Management of Atopic Eczema with Pimecrolimus Cream 1% (Elidel®) in Paediatric Patients. <i>Dermatology</i> , 2007, 215, 3-17.	2.1	30
157	Telangiectasia macularis eruptiva perstans (TMEP): A form of cutaneous mastocytosis with potential systemic involvement. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 885-891.e1.	1.2	30
158	Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteg cohort. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 2046-2054.	2.4	30
159	Efficacy of Ustekinumab in Palmoplantar Psoriasis. <i>Dermatology</i> , 2010, 221, 321-323.	2.1	29
160	Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 172-179.	2.4	29
161	Infection Due to <i>Klebsiella rhinoscleromatis</i> in Two Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 1993, 16, 441-442.	5.8	28
162	Conflicts of Interest in Dermatology. <i>Acta Dermato-Venereologica</i> , 2006, 86, 485-497.	1.3	28

#	ARTICLE	IF	CITATIONS
163	Prevalence and risk factors for fragility fracture in systemic mastocytosis. <i>Bone</i> , 2017, 105, 219-225.	2.9	28
164	Non-surgical treatments for hidradenitis suppurativa: A systematic review. <i>Annales De Chirurgie Plastique Et Esthetique</i> , 2017, 62, 274-294.	0.6	27
165	Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real-life practice. <i>British Journal of Dermatology</i> , 2019, 180, 1551-1552.	1.5	27
166	European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e308-e311.	2.4	27
167	Nickel-Induced Systemic Contact Dermatitis and Intratubal Implants. <i>Dermatitis</i> , 2013, 24, 35-36.	1.6	26
168	Inclusion and exclusion criteria in phase III trials with systemic agents in psoriasis: the external validity of drug development. <i>British Journal of Dermatology</i> , 2016, 175, 636-638.	1.5	26
169	<i>De novo</i> psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e296-e297.	2.4	26
170	Reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 434-443.	2.4	26
171	Topical methyl aminolevulinate photodynamic therapy for management of basal cell carcinomas in patients with basal cell nevus syndrome improves patients' satisfaction and reduces the need for surgical procedures. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 861-864.	2.4	25
172	Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. <i>European Journal of Dermatology</i> , 2012, 22, 762-769.	0.6	25
173	Socioeconomic outcomes following spinal cord injury and the role of no-fault compensation: longitudinal study. <i>Spinal Cord</i> , 2013, 51, 919-925.	1.9	25
174	Evidence-based recommendations on the role of dermatologists in the diagnosis and management of psoriatic arthritis: systematic review and expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 3-12.	2.4	25
175	Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum. <i>British Journal of Dermatology</i> , 2018, 178, 1199-1203.	1.5	25
176	Alternative Splicing Is Responsible for the Presence of Two Tissue Factor mRNA Species in LPS Stimulated Human Monocytes. <i>Thrombosis and Haemostasis</i> , 1992, 67, 272-276.	3.4	25
177	Efficacy, Safety and Tolerability of an Optimized Avulsion Technique with Onyster® (40% Urea) Tj ETQq1 1 0.784314 rgBT /Overlock Clinically Infected Nail in Toenail Onychomycosis: a Randomized Evaluator-Blinded Controlled Study. <i>Dermatology</i> , 2013, 226, 5-12.	2.1	24
178	Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). <i>British Journal of Dermatology</i> , 2014, 170, 425-434.	1.5	24
179	Validation of Treatment Escalation as a Definition of Atopic Eczema Flares. <i>PLoS ONE</i> , 2015, 10, e0124770.	2.5	24
180	Defects of corneocyte structural proteins and epidermal barrier in atopic dermatitis. <i>Biological Chemistry</i> , 2015, 396, 1163-1179.	2.5	24

#	ARTICLE	IF	CITATIONS
181	Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 405-411.	6.7	24
182	Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e362-e365.	2.4	24
183	Are we giving patients enough information on how to use topical treatments? Analysis of 767 prescriptions in psoriasis. <i>British Journal of Dermatology</i> , 2011, 165, 1332-1336.	1.5	23
184	Ixekizumab or secukinumab in psoriasis: what difference does it make?. <i>British Journal of Dermatology</i> , 2018, 178, 1003-1005.	1.5	23
185	Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3. <i>Journal of Dermatological Treatment</i> , 2019, 30, 19-26.	2.2	23
186	Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor- $\alpha$ blocking agents: two cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 967-968.	2.4	22
187	Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 301-309.	2.4	22
188	The evolving field of Dermat oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV, UEMS and EORTC Cutaneous Lymphoma Task Force. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2183-2197.	2.4	22
189	European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e839-e842.	2.4	22
190	Cutaneous Effects of Granulocyte Colony-Stimulating Factor in Healthy Volunteers. <i>Archives of Dermatology</i> , 1998, 134, 111-112.	1.4	22
191	Heterosexual behaviour and HIV risk in New Zealand: data from a national survey. <i>Australian Journal of Public Health</i> , 1995, 19, 13-18.	0.2	21
192	High-resolution magnetic resonance imaging in study of the skin: Normal patterns. <i>European Journal of Radiology</i> , 2011, 80, e176-e181.	2.6	21
193	Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 448-455.	2.4	21
194	The New Zealand cervical cancer study: could it happen again?. <i>BMJ: British Medical Journal</i> , 1988, 297, 533-539.	2.3	20
195	Healthcare cost impact of biological drugs compared with traditional systemic treatments in psoriasis: a cohort analysis in the French insurance database. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1235-1244.	2.4	20
196	Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 68-72.	2.4	20
197	Ascomycins in dermatology. <i>Seminars in Cutaneous Medicine and Surgery</i> , 1998, 17, 256-259.	1.6	19
198	Diagnosis of peripheral psoriatic arthritis: Recommendations for clinical practice based on data from the literature and experts opinion. <i>Joint Bone Spine</i> , 2009, 76, 532-539.	1.6	19

#	ARTICLE	IF	CITATIONS
199	A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque psoriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2566-2573.	2.4	19
200	Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1820-1825.	2.4	19
201	Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis. <i>Journal of Dermatology</i> , 2007, 34, 231-236.	1.2	18
202	Contact dermatitis to hydrolyzed wheat protein. <i>Contact Dermatitis</i> , 2007, 57, 283-284.	1.4	18
203	Antitumour necrosis factor- $\alpha$ therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013. <i>British Journal of Dermatology</i> , 2016, 174, 667-670.	1.5	18
204	Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study. <i>European Journal of Dermatology</i> , 2018, 28, 356-363.	0.6	18
205	Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. <i>Dermatology and Therapy</i> , 2022, 12, 61-78.	3.0	18
206	Point prevalence and risk factors for food allergy in a cohort of 386 children with atopic dermatitis attending a multidisciplinary dermatology/paediatric allergy clinic. <i>European Journal of Dermatology</i> , 2014, 24, 63-69.	0.6	17
207	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2317-2324.	2.2	17
208	Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 519-533.	6.5	17
209	Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 433-447.	6.7	17
210	Cutaneous T Cell Lymphoma Complicating Severe Atopic Dermatitis. <i>Dermatology</i> , 2009, 218, 168-171.	2.1	16
211	A Multicenter, Randomized, Open-Label, Controlled Study Comparing the Efficacy, Safety and Cost-Effectiveness of a Sequential Therapy with RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-Forming Solution with Amorolfine Nail Lacquer Alone in Dermatophytic Onychomycosis. <i>Dermatology</i> , 2013, 227, 157-164.	2.1	16
212	Breslow Thickness, Clark Index and Ulceration Are Associated with Sentinel Lymph Node Metastasis in Melanoma Patients: A Cohort Analysis of 612 Patients. <i>Dermatology</i> , 2014, 229, 183-189.	2.1	16
213	Bleomycin hydrolase downregulation in lesional skin of adult atopic dermatitis patients is independent of FLG gene mutations. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1459-1461.e7.	2.9	16
214	Active tuberculosis in psoriasis patients treated with TNF antagonists: a French nationwide retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1336-1341.	2.4	16
215	Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 115-121.	1.8	16
216	Reversibility of alexithymia with effective treatment of moderate-to-severe psoriasis: longitudinal data from EPIDEPSO. <i>British Journal of Dermatology</i> , 2019, 180, 397-403.	1.5	16

#	ARTICLE	IF	CITATIONS
217	Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. <i>British Journal of Dermatology</i> , 2021, 184, 640-651.	1.5	16
218	More on cutaneous reactions to recombinant cytokine therapy. <i>Journal of the American Academy of Dermatology</i> , 1996, 35, 650.	1.2	15
219	A prospective coagulation study including resistance to activated protein C and mutations in factors V and II in venous leg ulcers. <i>British Journal of Dermatology</i> , 1999, 141, 259-263.	1.5	15
220	Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: Development of recommendations for clinical practice based on data from the literature and experts opinion. <i>Joint Bone Spine</i> , 2009, 76, 524-531.	1.6	15
221	CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans. <i>Journal of Dermatological Science</i> , 2013, 69, 105-113.	1.9	15
222	Improvement of Microstomia in Scleroderma after Carbon Dioxide Laser Treatment. <i>Case Reports in Dermatology</i> , 2016, 8, 142-150.	0.8	15
223	Tumour lysis syndrome: an unexpected adverse event associated with ipilimumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e73-e74.	2.4	15
224	Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 807-815.	2.4	15
225	Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials. <i>Journal of Drugs in Dermatology</i> , 2018, 17, 200-206.	0.8	15
226	Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 2087-2100.	2.4	15
227	Moderate to severe psoriasis: from topical to biological treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1324-1326.	2.4	14
228	Factors associated with sun protection compliance: results from a nationwide cross-sectional evaluation of 2215 patients from a dermatological consultation. <i>British Journal of Dermatology</i> , 2014, 170, 1327-1335.	1.5	14
229	Positive change in hand care habits using therapeutic patient education in chronic hand eczema. <i>Contact Dermatitis</i> , 2020, 82, 10-17.	1.4	14
230	Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE 2 and 3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 450-457.	2.4	14
231	Enzalutamide induced acute generalized exanthematous pustulosis. <i>Journal of Dermatological Case Reports</i> , 2016, 10, 35-38.	1.1	14
232	Chromoblastomycosis with malignant transformation and cutaneous-synovial secondary localization. The potential therapeutic role of itraconazole. <i>Medical Mycology</i> , 1991, 29, 313-316.	0.7	13
233	Childhood chilblains is an uncommon and invalidant disease. <i>Archives of Disease in Childhood</i> , 2010, 95, 567-568.	1.9	13
234	Ocular damage in patients with psoriasis treated by Psoralen UV-A therapy or Narrow band UVB therapy: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 32-35.	2.4	13

#	ARTICLE	IF	CITATIONS
235	Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL). <i>Dermatology and Therapy</i> , 2020, 10, 1099-1109.	3.0	13
236	Impact of Atopic Dermatitis Lesion Location on Quality of Life in Adult Patients in a Real-world Study. <i>Journal of Drugs in Dermatology</i> , 2020, 19, 943-948.	0.8	13
237	Letter to <i>Dermatology</i> . <i>Dermatology</i> , 1999, 198, 320-323.	2.1	12
238	Simultaneous cutaneous infection due to <i>P</i> <i>aecilomyces lilacinus</i> and <i>A</i> <i>lternaria</i> in a heart transplant patient. <i>Transplant Infectious Disease</i> , 2012, 14, E156-60.	1.7	12
239	Contact Photoallergy to Isothipendyl Chlorhydrate. <i>Dermatology</i> , 2012, 224, 289-291.	2.1	12
240	Systemic allergic contact dermatitis caused by methyl aminolaevulinate in a patient with keratosisâ€œichthyosisâ€œdeafness syndrome. <i>Contact Dermatitis</i> , 2017, 76, 190-192.	1.4	12
241	Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 294-303.	2.4	12
242	Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance. <i>Clinical and Experimental Dermatology</i> , 2019, 44, e230-e234.	1.3	12
243	Therapeutic patient education and self-management support for patients with psoriasis â€œ a systematic review. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 685-695.	0.8	12
244	Integrated multidisciplinary approach to hidradenitis suppurativa in clinical practice. <i>International Journal of Women's Dermatology</i> , 2020, 6, 164-168.	2.0	12
245	Late-Onset X-Linked Dominant Protoporphyrria: An Etiology of Photosensitivity in the Elderly. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1688-1690.	0.7	11
246	Trichodysplasia spinulosa associated with HIV infection: clinical response to acitretin and valganciclovir. <i>Clinical and Experimental Dermatology</i> , 2018, 43, 231-233.	1.3	11
247	Latent class analysis categorizes chronic hand eczema patients according to skin barrier impairment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1529-1535.	2.4	11
248	Incidence of Auto-Immune Pemphigus in the Midi-PyrÃ©nÃ©es Region in 2002â€œ2006. <i>Dermatology</i> , 2010, 220, 97-102.	2.1	10
249	Development and psychometric validation of the REFlective evaluation of psoriasis Efficacy of Treatment and Severity ( REFLETS ) questionnaire: a common measure of plaque-type psoriasis severity and treatment efficacy for patients and clinicians. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 498-506.	2.4	10
250	A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features: results from psoriasis patients in Spain. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1176-1182.	2.4	10
251	Azathioprine Hypersensitivity Syndrome: Two Cases of Febrile Neutrophilic Dermatoses Induced by Azathioprine. <i>Case Reports in Dermatology</i> , 2017, 9, 6-11.	0.8	10
252	Infectious risk of biological drugs vs. traditional systemic treatments in moderate-to-severe psoriasis: a cohort analysis in the French insurance database. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 436-449.	1.9	10

#	ARTICLE	IF	CITATIONS
253	Stabilization of microtubules restores barrier function after cytokine-induced defects in reconstructed human epidermis. <i>Journal of Dermatological Science</i> , 2018, 91, 87-96.	1.9	10
254	Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases. <i>Clinical Immunology</i> , 2018, 194, 75-79.	3.2	10
255	Trends in hospitalization rates for psoriasis flares since the introduction of biologics: a time series in France between 2005 and 2015. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1920-1929.	2.4	10
256	Unmet medical needs in the treatment of atopic dermatitis in infants: An Expert consensus on safety and efficacy of pimecrolimus. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 414-424.	2.6	10
257	How to assess patient satisfaction regarding physician interaction: A systematic review. <i>Dermatologic Therapy</i> , 2021, 34, e14702.	1.7	10
258	Enhanced surveillance of HIV infections in New Zealand, 1996-1998. <i>New Zealand Medical Journal</i> , 2000, 113, 390-4.	0.5	10
259	Botulinum Toxin A: An Effective Treatment for Linear Immunoglobulin A Bullous Dermatitis Located in the Axillae. <i>Acta Dermato-Venereologica</i> , 2016, 96, 122-123.	1.3	9
260	Authorship selection in industry-sponsored publications of dermatology clinical trials. <i>British Journal of Dermatology</i> , 2017, 176, 1669-1671.	1.5	9
261	Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00683.	1.3	9
262	One-week terbinafine 1% solution in pityriasis versicolor: twice-daily application is more effective than once-daily. <i>Journal of Dermatological Treatment</i> , 2002, 13, 39-40.	2.2	8
263	Carbimazole-induced juvenile dermatomyositis. <i>British Journal of Dermatology</i> , 2007, 158, 071106220718008-???	1.5	8
264	Prognosis and follow-up of psoriatic arthritis with peripheral joint involvement: Development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2009, 76, 540-546.	1.6	8
265	Observational case series on a group of psoriasis patients who failed to respond to any TNF blockers. <i>Journal of Dermatological Treatment</i> , 2014, 25, 75-77.	2.2	8
266	Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis. <i>Clinical and Experimental Allergy</i> , 2016, 46, 133-141.	2.9	8
267	Higher prevalence of vertebral fractures in systemic mastocytosis, but not in cutaneous mastocytosis and idiopathic mast cell activation syndrome. <i>Osteoporosis International</i> , 2019, 30, 1235-1241.	3.1	8
268	Quality of care in atopic dermatitis – a position statement by the European Task Force on Atopic Dermatitis (<sc>ETFAD</sc>). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e136-e138.	2.4	8
269	Efficacy and safety of fixed-dose combination calcipotriol/betamethasone dipropionate foam for the treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 10-19.	2.4	8
270	Iatrogenic adrenal insufficiency associated with calcipotriol+betamethasone topical combination in psoriasis. <i>Clinical and Experimental Dermatology</i> , 2010, 35, e167-e168.	1.3	7

#	ARTICLE	IF	CITATIONS
271	Acquired perforating dermatosis associated with sorafenib therapy. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 328-330.	2.4	7
272	Conflicts of interest and authorship of industry-sponsored publications. British Journal of Dermatology, 2017, 176, 200-203.	1.5	7
273	Systemic treatment of severe adult Atopic dermatitis in clinical practice: analysis of prescribing pattern in a cohort of 241 patients. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e423-e424.	2.4	7
274	Changes in interleukin-17A, macrophage-derived chemokine and adiponectin following treatment of psoriasis with calcipotriol plus betamethasone dipropionate aerosol foam: results from the PSO-ABLE study. British Journal of Dermatology, 2018, 178, e33-e34.	1.5	7
275	Advanced Cutaneous Squamous Cell Carcinoma Is Associated with Suboptimal Initial Management in a Cohort of 109 Patients. Dermatology, 2019, 235, 516-521.	2.1	7
276	Profile of smoking dependency in hidradenitis suppurativa patients and smoking cessation outcomes. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e790-e791.	2.4	7
277	Blue nevus with satellitosis mimicking melanoma. Contribution of dermoscopy and reflectance confocal microscopy. Journal of Dermatological Case Reports, 2012, 6, 54-6.	1.1	7
278	Cytophagic Histiocytic Panniculitis after H1N1 Vaccination: A Case Report and Review of the Cutaneous Side Effects of Influenza Vaccines. Dermatology, 2011, 222, 217-220.	2.1	6
279	Is conjunctival mucous involvement a marker of severity in pemphigus vulgaris?. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 520-521.	2.4	6
280	Treatment (biotherapy excluded) of psoriatic arthritis: an appraisal of methodological quality of international guidelines. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 33-39.	2.4	6
281	Efficacy of ustekinumab in palmoplantar pustulosis. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e204-e206.	2.4	6
282	Frequency of isolated cutaneous involvement in adult mastocytosis: a cohort study. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1713-1718.	2.4	6
283	Langerhans cell histiocytosis associated with chronic myelomonocytic leukaemia both harbouring the same BRAF V600E mutation: efficacy of vemurafenib. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e120-e121.	2.4	6
284	Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort study. British Journal of Dermatology, 2022, 187, 602-603.	1.5	6
285	Incidence and risk factors for treatment failure with <i>infliximab</i> in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1323-1324.	2.4	5
286	Cardiovascular morbidity, risk of cancer and alcohol abuse in psoriasis: systematic literature reviews and expert opinion. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1-1.	2.4	5
287	Angiolymphoid hyperplasia with eosinophilia treated with low-dose methotrexate. JAAD Case Reports, 2015, 1, 342-344.	0.8	5
288	Immunohistochemical staining for diagnosis of cutaneous mastocytosis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e160-e162.	2.4	5

#	ARTICLE	IF	CITATIONS
289	Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease. <i>Dermatology</i> , 2018, 234, 23-30.	2.1	5
290	Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma. <i>Dermatology</i> , 2018, 234, 92-98.	2.1	5
291	Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e338-e341.	2.4	5
292	Prioritizing topics in guideline development: results of a two-phase online survey of dermatologist members of the EADV. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 227-233.	2.4	5
293	Out-of-pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross-sectional, non-comparative, multicentre study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 912-918.	2.4	5
294	First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort PsobioTeq. <i>Dermatology</i> , 2021, 237, 338-346.	2.1	5
295	Diagnostic du rhumatisme psoriasique de forme pŕiphrŕique : ŕlaboration de recommandations pour la pratique clinique, ŕ partir d'une analyse systématique de la littérature et de l'opinion d'experts. <i>O.O Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 15-22.		4
296	Analysis of non-responders to dupilumab in clinical practice: a cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e192-e194.	2.4	4
297	Tapinarof-induced folliculitis: The paradigm of activation of the aryl hydrocarbon signaling pathway. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, e37-e38.	1.2	4
298	Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Psoriasis Patients from the PsoBioTeq Cohort. <i>Acta Dermato-Venereologica</i> , 2021, , .	1.3	4
299	Distal Madelung-Launois-Bensaude disease: an unusual differential diagnosis of acromelic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2008, 26, 351-3.	0.8	4
300	Treating Severe Psoriasis: How to Navigate Safely Between Scylla and Charybdis?. <i>Journal of Investigative Dermatology</i> , 2003, 121, ix-x.	0.7	3
301	Cancer Risk Evaluation in Psoriasis: In Search of the Holy Grail?. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2547-2549.	0.7	3
302	Albright hereditary osteodystrophy: report of a particular clinical phenotype caused by a novel GNAS mutation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 974-975.	2.4	3
303	Academic mentorship in dermatology. <i>British Journal of Dermatology</i> , 2015, 173, 1113-1114.	1.5	3
304	Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 118.	2.7	3
305	How Oral Specialists Can Help Diagnose and Manage Extra-Digestive Inflammatory Bowel Disease Complications. <i>Case Reports in Gastroenterology</i> , 2021, 15, 276-281.	0.6	3
306	A Multicentre Randomised Controlled Study Evaluating the Effect of a Standardised Education Programme on Quality of Life, Disease Severity, and Disease Knowledge in Patients with Moderate-To-Severe Psoriasis: The EDUPSO Study. <i>Dermatology</i> , 2021, , 1-10.	2.1	3

#	ARTICLE	IF	CITATIONS
307	Oral contraceptive use and risk of breast cancer in older women (New Zealand). <i>Cancer Causes and Control</i> , 1995, 6, 485-491.	1.8	2
308	Milia complicating bullous polymorphic light eruption. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2009, 25, 51-52.	1.5	2
309	Psoriasis evaluation in clinical practice: systematic review and expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1-1.	2.4	2
310	Purpuric lesions induced by UVA1 spectrum (340-400nm) phototesting in an adult with persistent and severe hydroa vacciniforme. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2010, 26, 104-106.	1.5	2
311	Dermatite atopique de l'enfant : quand penser à l'allergie alimentaire ?. <i>Revue Francaise D'allergologie</i> , 2010, 50, S14-S20.	0.2	2
312	Use of conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1-1.	2.4	2
313	Traitement du psoriasis en pratique pour le rhumatologue. <i>Revue Du Rhumatisme Monographies</i> , 2011, 78, 145-151.	0.0	2
314	Buprenorphine-induced linear IgA bullous dermatosis –œdown the rail. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, e106-e107.	1.2	2
315	Photo-induced graft-versus-host disease. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2016, 32, 291-295.	1.5	2
316	Efficacy of hospital inpatient topical treatment for severe adult atopic dermatitis: a retrospective study of 56 patients. <i>European Journal of Dermatology</i> , 2017, 27, 418-419.	0.6	2
317	Mast cell activation syndrome: High frequency of skin manifestations and anaphylactic shock. <i>Allergy International</i> , 2019, 68, 119-121.	3.3	2
318	Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. <i>Quality of Life Research</i> , 2020, 29, 369-380.	3.1	2
319	532 nm Q-switched laser for the treatment of hyperpigmentation induced by topical tacrolimus. <i>Journal of Cosmetic and Laser Therapy</i> , 2020, 22, 90-92.	0.9	2
320	Characteristics of patients with psoriasis with Psoriasis Area and Severity Index <math>\geq 10</math> treated with biological agents: results from the French PsoBioTeq cohort. <i>British Journal of Dermatology</i> , 2021, 185, 1052-1054.	1.5	2
321	Cav1.4 calcium channels control cytokine production by human peripheral TH17 cells and psoriatic skin-infiltrating T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2021, , .	2.9	2
322	Skin manifestations of hypereosinophilic syndrome are polymorphous and difficult to treat: A retrospective cohort study. <i>Annales De Dermatologie Et De Venereologie</i> , 2022, 149, 139-141.	1.0	2
323	No new evidence on the cervical cancer study. <i>New Zealand Medical Journal</i> , 1990, 103, 581-3.	0.5	2
324	Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00672.	1.3	2

#	ARTICLE	IF	CITATIONS
325	Efficacy and tolerability of long-pulse Alexandrite laser hair removal for hidradenitis suppurativa. <i>European Journal of Dermatology</i> , 2021, , .	0.6	2
326	Impact of Childhood Onset Psoriasis on Addictive Behaviours, Socioeconomic and Educational Data in Adulthood. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00733.	1.3	2
327	Screening for hepatitis B carriers: A perspective from New Zealand. <i>Australian and New Zealand Journal of Medicine</i> , 1997, 27, 698-705.	0.5	1
328	Importance of trial design in studies using high-dose intravenous immunoglobulin: reply from authors. <i>British Journal of Dermatology</i> , 2003, 148, 1285-1286.	1.5	1
329	Management of Autoimmune Bullous Diseases in France: A Nationwide Network of 30 Centers. <i>Dermatologic Clinics</i> , 2011, 29, 659-662.	1.7	1
330	Joint clinical and pathological review meetings improve patient care: a prospective evaluation in dermatology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 928-932.	2.4	1
331	Topical treatment and phototherapy in psoriasis: systematic review and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, iii-iv.	2.4	1
332	GRAPPA Fellows Symposium Adjacent to the Swiss Psoriasis Day, Geneva, 2014: A Meeting Report. <i>Journal of Rheumatology</i> , 2015, 42, 1014-1015.	2.0	1
333	Surgical Treatment of Facial Basal Cell Carcinoma: Patient-Based Assessment of Clinical Outcome in a Prospective Cohort Study. <i>Dermatology</i> , 2016, 232, 550-557.	2.1	1
334	Focal facial hyperhidrosis associated with internal carotid artery dissection successfully treated with botulinum toxin A. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e314-e316.	2.4	1
335	Early necrotic skin lesions after a ABO incompatible kidney transplantation: The threat of Cunnighamella Spp.. <i>Transplant Infectious Disease</i> , 2019, 21, e13173.	1.7	1
336	Image Gallery: The vulva: an atypical localization of mastocytosis in adulthood. <i>British Journal of Dermatology</i> , 2019, 181, e33.	1.5	1
337	An oral manifestation of IBD: Pyostomatitis vegetant, about two cases. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , 2019, 120, 375-377.	1.3	1
338	Compounded topical preparations in plaque psoriasis: Still a place for it in 2018?. <i>Dermatologic Therapy</i> , 2019, 32, e12780.	1.7	1
339	Vascular Nd:YAG laser: a therapeutic alternative for large venous lakes of the oral mucosa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e164-e165.	2.4	1
340	Use of Complementary and Alternative Medicines by Patients with Psoriasis: Results from a Study with 2562 Patients. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 285-287.	6.7	1
341	A nationwide study evaluating the association of autoimmune bullous diseases and acquired haemophilia: description of clinical and prognostic features. <i>British Journal of Dermatology</i> , 2021, , .	1.5	1
342	Dermatite atopique Traitements actuels et traitements d'avenir. <i>Revue Francaise D'allergologie Et D'immunologie Clinique</i> , 1997, 37, 361-366.	0.1	0

#	ARTICLE	IF	CITATIONS
343	Topical tacrolimus and pimecrolimus are not associated with skin atrophy: reply from author. British Journal of Dermatology, 2002, 146, 343-343.	1.5	0
344	Pronostic et suivi du rhumatisme psoriasique de forme pŕiphrŕique : ŕlaboration de recommandations pour la pratique clinique, ŕ partir dŕune analyse systŕmatique de la littŕature et de lŕopinion dŕexperts. Revue Du Rhumatisme (Edition Francaise), 2007, 74, 23-30.	0.0	0
345	Les traitements mŕdicamenteux (hors biothŕrapie) dans la prise en charge de patients atteints de rhumatisme psoriasique pŕiphrŕique : ŕlaboration de recommandations pour la pratique clinique, ŕ partir dŕune analyse systŕmatique de la littŕature et de lŕopinion dŕexperts. Revue Du Rhumatisme (Edition Francaise). 2007, 74, 31-38.	0.0	0
346	New topical drug development in atopic dermatitis: a place for hope. British Journal of Dermatology, 2012, 166, 711-711.	1.5	0
347	Risk factors, diagnosis and management of psoriatic arthritis: systematic literature reviews and expert opinion of a panel of dermatologists. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1-2.	2.4	0
348	Real World Skin Clearance Rates for Biologic Treatments In Patients With Moderate to Severe Plaque Psoriasis: Interim Results From A Large Prospective, Observational Study. Value in Health, 2015, 18, A429.	0.3	0
349	Caractŕistiques clinico-biologiques des mastocytoses suivies en rhumatologie. Revue Du Rhumatisme (Edition Francaise), 2016, 83, A136-A137.	0.0	0
350	Palmar erythema: inaugural manifestation of HIV infection. European Journal of Dermatology, 2017, 27, 668-669.	0.6	0
351	Therapeutische Patientenschulungsprogramme und Unterstŕtzung beim Selbstmanagement fŕr Patienten mit Psoriasis ŕ eine systematische ŕbersicht. JDDG - Journal of the German Society of Dermatology, 2019, 17, 685-697.	0.8	0
352	Acrodermatitis enteropathica-like eruption secondary to vitamin and amino acid deficiencies associated with pancreatic tumour. Annales De Dermatologie Et De Venereologie, 2021, 148, 133-135.	1.0	0
353	Cutaneous mastocytosis in adults with a serum tryptase level < 20 ng mL ŕ1 : why we should investigate further. British Journal of Dermatology, 2021, 185, 453-455.	1.5	0
354	What instruments should we add to our toolbox for measuring the severity and control of eczema?. British Journal of Dermatology, 2021, 185, 13-14.	1.5	0
355	Dermatose ŕ IgA linŕaire sŕvŕre compliquŕe dŕune aspergillose invasive. La Presse Mŕdicale Formation, 2021, 2, 303-306.	0.1	0
356	Complications oculaires induites par le dupilumab au cours du traitement de la dermatite atopique. Revue Francaise D'allergologie, 2021, 61, 592-592.	0.2	0
357	Psoriasis, conception and pregnancy: expectations and perspectives. European Journal of Dermatology, 2020, 30, 2-2.	0.6	0
358	Retrospective Study of Midodrine as a Method of Decreasing Length of Vasopressor Support in the ICU. , 2022, , .		0
359	Decision-making factors for the long-term topical treatment of mild-to-moderate plaque psoriasis: TEPPSO, a case-vignette study on clinical practice. Annales De Dermatologie Et De Venereologie, 2022, , .	1.0	0